{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:44:34Z","timestamp":1767912274906,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005035","name":"Biotronik","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006520","name":"Edwards Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008645","name":"Terumo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.amjcard.2019.06.021","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T11:07:12Z","timestamp":1563188832000},"page":"1020-1026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-9226","authenticated-orcid":false,"given":"Ron","family":"Waksman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0907-5258","authenticated-orcid":false,"given":"Evan","family":"Shlofmitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques J.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Kandzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Lipinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Torguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.06.021_bib0001","unstructured":"National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services, 2014."},{"key":"10.1016\/j.amjcard.2019.06.021_bib0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"Farkouh","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0003","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0140-6736(14)61038-2","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial","volume":"384","author":"Pilgrim","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II Trial","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"13 Supplement","key":"10.1016\/j.amjcard.2019.06.021_bib0005","doi-asserted-by":"crossref","first-page":"B283","DOI":"10.1016\/j.jacc.2018.08.1924","article-title":"TCT-707 A prospective randomized multicenter study to assess the safety and effectiveness of the orsiro sirolimus eluting stent in the treatment of subjects with up to two de novo coronary artery lesions\u2013BIOFLOW IV: 3 year clinical results","volume":"72","author":"Slagboom","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0006","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(17)32249-3","article-title":"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularization (BIOFLOW V): a randomized trial","volume":"390","author":"Kandzari","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0007","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.4244\/EIJV8I9A155","article-title":"Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study","volume":"8","author":"Hamon","year":"2013","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0008","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.carrev.2017.02.016","article-title":"BIOFLOW-III satellite-One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance","volume":"18","author":"Kornowski","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jacc.2018.05.052","article-title":"Erythrocytes from patients with type 2 diabetes induce endothelial dysfunction via arginase I","volume":"72","author":"Zhou","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0010","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2337\/diacare.24.8.1476","article-title":"Platelet dysfunction in type 2 diabetes","volume":"24","author":"Vinik","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003803","article-title":"Comparison of vascular responses following new-generation biodegradable and durable polymer-based drug-eluting stent implantation in an atherosclerotic rabbit iliac artery model","volume":"5","author":"Nakazawa","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcin.2016.11.023","article-title":"Labeling stents\/scaffolds for diabetes: real science or marketing stunt?","volume":"10","author":"Waksman","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002328","article-title":"High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish Coronary Angiography and Angioplasty Registry","volume":"8","author":"Ritsinger","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0014","first-page":"221","article-title":"Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: a meta-analysis of 10 RCTs with 6575 patients","volume":"1","author":"Wu","year":"2015","journal-title":"Chronic Dis Transl Med"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0015","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","article-title":"Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II Trial","volume":"11","author":"Lef\u00e8vre","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.002319","article-title":"Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial","volume":"8","author":"Franzone","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003255","article-title":"Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE Trial","volume":"5","author":"Zbinden","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0018","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial","volume":"392","author":"Pilgrim","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0019","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.amjcard.2018.07.040","article-title":"Meta-analysis of the impact of strut thickness on outcomes in patients with drug-eluting stents in a coronary artery","volume":"122","author":"Iantorno","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0020","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijcard.2014.09.143","article-title":"Impact of stent strut design in metallic stents and biodegradable scaffolds","volume":"177","author":"Foin","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0021","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jcin.2016.03.038","article-title":"Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds: Evidence From a Network Meta-Analysis of 147 Trials","volume":"9","author":"Kang","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0022","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/S0140-6736(16)31920-1","article-title":"Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial","volume":"388","author":"von Birgelen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007331","article-title":"Subgroup analysis comparing ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in acute coronary syndrome patients BIOFLOW V acute coronary syndromes subgroup","volume":"11","author":"Roguin","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0024","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","article-title":"Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial","volume":"392","author":"Pilgrim","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0025","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.693739","article-title":"Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization","volume":"115","author":"Finn","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0026","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jcin.2016.02.025","article-title":"Incidence and clinical outcomes of stent fractures on the basis of 6,555 patients and 16,482 drug-eluting stents from 4 centers","volume":"9","author":"Kan","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0027","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0028","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamacardio.2016.5190","article-title":"Five-year outcome after implantation of zotarolimus- and everolimus-eluting stents in randomized trial participants and nonenrolled eligible patients: a secondary analysis of a randomized clinical trial","volume":"2","author":"von Birgelen","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0029","first-page":"387","volume":"91","author":"Campos","year":"2018","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2019.06.021_bib0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcin.2012.11.006","article-title":"Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program","volume":"6","author":"Silber","year":"2013","journal-title":"JACC Cardiovasc Interv"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919307659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919307659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:29:32Z","timestamp":1757572172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919307659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0002914919307659"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.06.021","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}